Sign up Australia
Proactive Investors - Run By Investors For Investors

Compumedics' shares soar on China expansion

Compumedics is monetising its sleep technology in China.
Compumedics' shares soar on China expansion
The Somfit platform covers sleep and associated disorders

Compumedics Ltd's (ASX:CMP) shares have soared 71% to $0.70 in the first hour of trade, with two million changing hands.

The investor momentum has been driven by the company entering into a joint venture with Meinian Onehealth Healthcare Holdings Co., Ltd. (Health 100) – a leading China-based premium health-check organisation.

A framework agreement has been signed with a period of 90 days to execute the joint venture, with Compumedics to hold 49% and Health 100 the remaining 51%.
           
Dr David Burton, chairman and CEO of Compumedics, commented:

"Compumedics and Health 100 have been in discussions for some time now about the way both parties, together with the Somfit product and technology platform, can transform sleep and brain healthcare in China."

What is Somfit

Somfit is the first of its kind consumer-level, medical-grade wireless wearable sleep system, incorporating Compumedics’ widely deployed and validated ‘gold standard’ sleep analytics.

Somfit technology allows everyone, everywhere, anytime to access personalised management of true-sleep measures based on Compumedics’ proven and widely deployed sleep analytics.

The Somfit platform covers sleep and associated disorders, including sleep-disorder breathing, sleep treatment devices, cardiology, respirology, neurology and diabetes, among other sleep-related health management disciplines.

In addition to the deployment of 1 million Somfit systems and associated health management platforms and device eco-systems, the joint venture also involves the establishment of Health 100’s sleep management network spanning the Health 100 centres in Greater China.

Joint venture financials

Compumedics will receive a $11.3 million pre-tax payment as an upfront payment in part for providing the joint venture with the Somfit-related intellectual property and technology rights for the Greater China region.

Health 100 will commit to purchasing an initial 1 million Somfit devices for the China market in the first two years following the Somfit device receiving China Food and Drug Administration (CFDA) approval.

Compumedics said this sale will generate at least $133 million revenue to the joint venture over this period.

View full CMP profile View Profile

Compumedics Ltd Timeline

Newswire
September 21 2016

Related Articles

Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards
3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use